HC Wainwright Cuts BioLineRx (NASDAQ:BLRX) Price Target to $9.00

BioLineRx (NASDAQ:BLRX) had its price target decreased by HC Wainwright from $21.00 to $9.00 in a report released on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.

Separately, StockNews.com began coverage on shares of BioLineRx in a report on Sunday. They issued a “hold” rating for the company.

BioLineRx Trading Up 3.9 %

BioLineRx stock opened at $0.29 on Monday. BioLineRx has a 52 week low of $0.25 and a 52 week high of $1.89. The company has a quick ratio of 1.49, a current ratio of 1.61 and a debt-to-equity ratio of 1.34. The company has a market capitalization of $22.94 million, a price-to-earnings ratio of -1.27 and a beta of 1.48. The stock has a 50-day moving average price of $0.48 and a 200 day moving average price of $0.61.

Institutional Trading of BioLineRx

A number of institutional investors have recently added to or reduced their stakes in BLRX. CVI Holdings LLC purchased a new position in BioLineRx during the second quarter worth $462,000. Atria Investments Inc grew its holdings in shares of BioLineRx by 27.9% during the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 29,193 shares during the period. Finally, PVG Asset Management Corp purchased a new position in shares of BioLineRx in the 2nd quarter valued at $70,000. Hedge funds and other institutional investors own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.